SNAI1 and neoplasm: In this study, we show that Snail1 is a driver of CAFs-induced immunosuppression and pro-tumour immunity in melanoma, that its expression correlates with impaired responses to immune checkpoint inhibitors and therefore, we confirm its potential as a therapeutic target.